Literature DB >> 31984866

Graves' Disease and Toxic Nodular Goiter, Aggravated by Duration of Hyperthyroidism, Are Associated with Alzheimer's and Vascular Dementia: A Registry-Based Long-Term Follow-Up of Two Large Cohorts.

Lars Folkestad1,2,3, Frans Brandt4,5, Mads Lillevang-Johansen1,2,3, Thomas Heiberg Brix1,3, Laszlo Hegedüs1,3.   

Abstract

Background: Dementia is an increasing burden to the health care system. It is currently debated whether hyperthyroidism is associated with a risk of dementia. Our aim was to determine the risk of dementia in hyperthyroid individuals and whether this was associated with duration of hyperthyroidism.
Methods: Risk of dementia in hyperthyroid individuals was evaluated in two cohorts and matched reference populations. The Danish National Patient Registry (DNPR) cohort is a registry-based Danish nationwide cohort followed for a median of 7.2 years (from 1995 to 2013), whereas the OPENTHYRO registry cohort comprises 235,547 individuals who had at least one serum thyrotropin (TSH) measurement in the period from 1995 to 2011 and was followed for a median of 7.3 years. Each hyperthyroid case was matched with four controls according to age and sex using density sampling. Hyperthyroidism was defined as either an International Classification of Diseases Version 10 (ICD-10) diagnosis of toxic nodular goiter (TNG) or Graves' disease (GD), or two measurements of a TSH below 0.3 mU/L in the DNPR and OPENTHYRO registry cohort, respectively. The primary outcome was all-cause dementia, defined as either an ICD-10 code of dementia or prescription of medicine for dementia, with subgroup analyses of vascular dementia and Alzheimer's disease.
Results: The DNPR cohort had 56,128 patients with hyperthyroidism, 2689 of whom were registered with dementia. The reference population had 224,512 individuals, of whom 10,199 had dementia (hazard ratio 1.17; 95% confidence interval [CI]: 1.12-1.23). Risk of dementia, whether Alzheimer's or vascular, was higher in both GD and TNG. The OPENTHYRO registry cohort constituted 2688 hyperthyroid individuals and 10,752 euthyroid control individuals of whom 190 and 473 individuals, respectively, were subsequently diagnosed with dementia (HR 1.06; 95% CI: 0.89-1.26). For each 6 months of decreased TSH, the risk of all-cause dementia was significantly higher (HR 1.16; 95% CI: 1.12-1.22). Conclusions: Using large-scale registry-based data, we found increased risk of dementia in hyperthyroid individuals. Every 6 months of decreased TSH was associated with increased risk of dementia by 16%, compared with individuals with normal TSH. Our data support early diagnosis and intervention in patients with hyperthyroidism.

Entities:  

Keywords:  Graves' disease; dementia; epidemiology; hyperthyroidism; toxic nodular goiter

Mesh:

Year:  2020        PMID: 31984866     DOI: 10.1089/thy.2019.0672

Source DB:  PubMed          Journal:  Thyroid        ISSN: 1050-7256            Impact factor:   6.568


  8 in total

1.  "Quid autem vides festucam in oculo fratris tui et trabem in oculo tuo non vide" on the hyperthyroidism-induced mortality and antithyroid drug-induced side effects in the era of radioiodine fake news.

Authors:  Luca Giovanella; Frederik A Verburg; Petra Petranović Ovčariček; Ioannis Iakovou; Jasna Mihailovic; Alexis Vrachimis; Slimane Zerdoud; Martha Hoffmann; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-06       Impact factor: 9.236

2.  Analysis of the Application Value of Ultrasound Three-Dimensional Speckle Tracking Technology Combined with Thyroid Autoantibodies and Hormones in the Diagnosis and Treatment of Graves' Disease.

Authors:  Yi Xu; Songxia Peng; Li Qin; Dianjing Sun; Jianlin Geng; Qingqing Liu
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-06       Impact factor: 2.650

Review 3.  Primary hypothyroidism and quality of life.

Authors:  Laszlo Hegedüs; Antonio C Bianco; Jacqueline Jonklaas; Simon H Pearce; Anthony P Weetman; Petros Perros
Journal:  Nat Rev Endocrinol       Date:  2022-01-18       Impact factor: 47.564

4.  Blood-based biomarkers in hypothalamic-pituitary axes for the risk of dementia or cognitive decline: a systematic review and meta-analysis.

Authors:  Yi-Jun Ge; Wei Xu; Chen-Chen Tan; Lan Tan
Journal:  Aging (Albany NY)       Date:  2020-10-26       Impact factor: 5.682

Review 5.  Enhanced Well-Being Associated with Thyrotoxicosis: A Neglected Effect of Thyroid Hormones?

Authors:  Petros Perros; Laszlo Hegedus
Journal:  Int J Endocrinol Metab       Date:  2022-05-29

6.  Modulating Thyroid Hormone Levels in Adult Mice: Impact on Behavior and Compensatory Brain Changes.

Authors:  Dana M Niedowicz; Wang-Xia Wang; Doug A Price; Peter T Nelson
Journal:  J Thyroid Res       Date:  2021-06-24

7.  Patient-Tailored Levothyroxine Dosage with Pharmacokinetic/Pharmacodynamic Modeling: A Novel Approach After Total Thyroidectomy.

Authors:  Vegard Heimly Brun; Amund H Eriksen; Ruth Selseth; Kenth Johansson; Renate Vik; Benedicte Davidsen; Michal Kaut; Lars Hellemo
Journal:  Thyroid       Date:  2021-06-22       Impact factor: 6.568

8.  The Association Between Thyroid Diseases and Alzheimer's Disease in a National Health Screening Cohort in Korea.

Authors:  Ji Hee Kim; Heui Seung Lee; Yoo Hwan Kim; Mi Jung Kwon; Joo-Hee Kim; Chan Yang Min; Dae Myoung Yoo; Hyo Geun Choi
Journal:  Front Endocrinol (Lausanne)       Date:  2022-03-07       Impact factor: 5.555

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.